The observation in recent years the hospital market, biochemical medicine and biotechnology drugs has become an important variety of indispensable, Human Albumin and Thymosin two drugs in major surgery, cancer treatment, improve the cellular immune function play a certain role, and further prove that the biological enterprises in China has embarked on a rapid development of the train.

What is thymosin?

Thymosin is a kind of polypeptide compound exists in mammalian thymus, and immune cell differentiation molecules, with the differentiation and proliferation of T lymphocytes, improve immune function, can damage the target cell infection, can also activate NK cells, cytokines and promoting immune related production is a composite treatment of chronic hepatitis B and immunodeficiency syndrome drugs in non small cell lung cancer and malignant melanoma treatment also played a large role.

Thymus peptide was first extracted from calf thymus by Serono company, and was listed in Italy in 1980. After the successful development of China in the middle of 1980s. Officially approved as "immunomodulator", put into production, named thymosin, 1998, thymosin tablets and capsules have also been approved by the Ministry of health.

The commonly used thymosin preparations and Thymosin alpha 1, thymosin alpha 1 in thymus is single component polypeptide, sciclone Sciclone developed in 1997 by the 24 countries listed, has been approved for the treatment of chronic hepatitis B HBV, in Europe and Japan and other countries are also used for the treatment of hepatitis C, liver cell HCV cancer and enhance the treatment of immune diseases, thymus sciclone company alpha 1 has been registered in china.

Peptide products: domestic Human Albumin has become mainstream

Our treatment of commonly used drugs include Human Albumin, injection and lyophilized, both in clinical plays an important role, but also for the hospital in the best-selling brand, in the key city sample hospital drug list, for seven consecutive years ranked second.

According to the national key city DDDs analysis shows that Human Albumin in 2001 was 218 million yuan, increased to 302 million yuan in 2003, compared with the previous year growth of 15.78%, of which imports: Human Albumin is only 8.18%, domestic drugs accounted for 91.82%, thus becoming the mainstream in the market.

Recalling the development process of the product, before 1995, China's production of injection with Human Albumin's biological products and enterprises have 11, and by 1999 has reached 31. At present, through the national fixed-point and through the GMP certification of blood products production unit 36, all achieved automatic filling production line, so as to meet the needs of the market. Since 2001 the Tiantan Biological Products Corporation products formed the scale of production, domestic Human Albumin gradually occupy a major share of the market, in 2002 our country has a certain scale of production enterprises has reached 13, the annual output is 733 million.

Domestic thymosin market share of about 1 billion yuan

In recent years, China's thymosin products from production to sales has been expanding, the market growth rate is faster. National Development and Reform Commission, the Medical Information Center released data show that: China's 2001 output of 3089 tons of thymosin, an increase of more than 2 times last year. In 2002 China affected by the SARS epidemic, thymosin market demand rapid increase in the amount of sales, all the way through, the injection of 5mg extrasin yield is 32 million 870 thousand, the main manufacturer is Xi'an Diesel bio pharmaceutical industry, accounting for about 64.74%. In addition, Hunan langlifu pharmaceutical, Kazakhstan Gaoke White Swan pharmaceutical, Heilongjiang pharmaceutical and medical Bethune Dillon anda pharmaceutical production accounted for 25%, estimated market share of about 1 billion yuan of thymopeptides.